Target intelligence / Profile preview

Pantothenate kinase 1 (PANK1)

Target
PANK1
Molecular classification
Enzyme (protein kinase, specifically serine/threonine kinase), Regulatory enzyme (Pantothenate kinase family)
01

Overview

Pantothenate kinase 1 (PANK1) is an enzyme that catalyzes the first and rate-limiting step in coenzyme A biosynthesis by converting pantothenic acid to 4'-phosphopantothenate. It plays a crucial role in cellular metabolism and energy homeostasis, regulating the acetyl-CoA/CoA ratio necessary for fatty acid metabolism, the citric acid cycle, and protein acetylation. PANK1 exerts additional biological functions as a negative regulator of Wnt/β-catenin signaling via cooperative phosphorylation of β-catenin (with CK1α), impacting cell growth and cancer progression. It is tightly regulated both by metabolic products (feedback inhibition by CoA and its thioesters) and at the transcriptional level by the tumor suppressor p53. Dysfunction or altered expression of PANK1 is implicated in cancer, neurodegeneration, and metabolic syndromes.

Other names
Pantothenate kinase 1PANK1PANKhPanKhPanK1MGC24596PANK1aPANK1bPantothenic acid kinase 1
02

Mechanism of action

Drugs may target the kinase activity to modulate CoA biosynthesis or β-catenin stability (e.g., inhibition suppresses phosphorylation of β-catenin, affects Wnt/β-catenin signaling). CoA thioesters exert feedback inhibition; drugs that mimic this mechanism can regulate its activity.

03

Biological functions

Coenzyme A biosynthesis (rate-limiting step)Regulation of acetyl-CoA/CoA ratio, which affects energy and lipid metabolismNegative regulation of Wnt/β-catenin signaling through phosphorylation of β-cateninCell proliferation control via protein kinase activityRegulated by p53, involved in metabolic stress response, gluconeogenesis, and fatty acid β-oxidation
04

Disease associations

Cancer (e.g., hepatocellular carcinoma, via modulation of β-catenin and Wnt signaling)Neurodegenerative disease (Neurodegeneration with brain iron accumulation subtypes)Metabolic disorders (impaired fatty acid metabolism, gluconeogenesis)
05

Safety considerations

Altered PANK1 activity can impair fatty acid β-oxidation, gluconeogenesis, and lipid metabolismPotential secondary effects on tumor progression due to modulation of Wnt/β-catenin and metabolic pathways
06

Interacting drugs

Bezafibrate (induces expression in liver)

1 more in the full profile.

07

Biomarkers

PANK1 and β-catenin expression levels serve as prognostic biomarkers in hepatocellular carcinomaPotential CoA and acetyl-CoA ratio in tissues for metabolic monitoring

Beyond the preview

Go deeper on Pantothenate kinase 1 (PANK1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pantothenate kinase 1 (PANK1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call